Gracell Bio rises as China greenlights bone marrow cancer therapy trial

Gracell Biotechnologies

13/02/2023 12:55

** Shares of China-based drug developer Gracell
Biotechnologies  GRCL.O  up 1.4% at $2.2
    ** Chinese regulators clear Gracell's application to start
human trials for its bone marrow cancer therapy in the country
 urn:newsml:reuters.com:*:nPn1YZt0sa
    ** Gracell plans to initiate early-to-mid-stage trial in
China in Q3 2023
    ** On Feb 3, FDA cleared Gracell's application to begin
human trials in United States; co plans to initiate an
early-to-mid-stage trial in Q2
    ** Up to last close, stock down 5.7% YTD
 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((nandhini.srinivasan@thomsonreuters.com))